Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TERT | O14746 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158907 | 1.00 | FAAH (0.54) | FAAHTRPV1TSHRTERTPTPN1 | |
| SCHEMBL2163660 | 1.00 | FAAH (0.54) | FAAHTRPV1TSHRTERTPTPN1 | |
| SCHEMBL2163401 | 1.00 | FAAH (0.54) | FAAHTRPV1TSHRTERTPTPN1 | |
| SCHEMBL16431159 | 1.00 | FAAH (0.54) | FAAHTRPV1TSHRTERTPTPN1 | |
| SCHEMBL910497 | 1.00 | FAAH (0.54) | FAAHTRPV1TSHRTERTPTPN1 | |
| SCHEMBL548514 | 1.00 | FAAH (0.54) | FAAHTRPV1TSHRTERTPTPN1 | |
| SCHEMBL548521 | 1.00 | FAAH (0.54) | FAAHTRPV1TSHRTERTPTPN1 | |
| SCHEMBL158906 | 1.00 | FAAH (0.54) | FAAHTRPV1TSHRTERTPTPN1 | |
| SCHEMBL9696115 | 1.00 | FAAH (0.54) | FAAHTRPV1TSHRTERTPTPN1 | |
| SCHEMBL415112 | 1.00 | FAAH (0.54) | FAAHTRPV1TSHRTERTPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852758-B2 | Oil composition | KAO CORPORATION (JP) | 2005-02-08 | — | — | US | claimed |
| US-6762203-B2 | MIXTURE OF GLYCERIDES, TRIGLYCERIDES AND FATTY ACID; FOODS, DRUGS | KAO CORPORATION (JP) | 2004-07-13 | — | — | US | claimed |
| US-20030072858-A1 | Oil composition | KAO CORPORATION (JP) | 2003-04-17 | — | — | US | claimed |
| US-20020048596-A1 | PREPARATION FOR THE TRANSPORT OF AN ACTIVE SUBSTANCE ACROSS BARRIERS | IDEA AG (DE) | 2002-04-25 | — | — | US | claimed |
| US-20240099976-A1 | BLENDED FORMULATIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2024-03-28 | — | — | US | disclosed |
| US-20240009092-A1 | COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID | NIPPON SHOKUBAI CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| US-11547665-B2 | Multiphasic compositions | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2023-01-10 | — | — | US | disclosed |
| EP-3954361-A1 | MULTIPHASIC COMPOSITIONS | Sequessome Technology Holdings Limited (MT) | 2022-02-16 | — | — | EP | disclosed |
| US-20210393655-A1 | Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2021-12-23 | — | — | US | disclosed |
| EP-3316857-B1 | MULTIPHASIC COMPOSITIONS | SEQUESSOME TECH HOLDINGS LIMITED (MT) | 2021-08-04 | — | — | EP | disclosed |
| EP-3316856-B1 | BLENDED FORMULATIONS | SEQUESSOME TECH HOLDINGS LIMITED (MT) | 2021-04-07 | — | — | EP | disclosed |
| US-20210023007-A1 | BLENDED FORMULATIONS | SEQUESSOME TECH HOLDINGS LIMITED (US) | 2021-01-28 | — | — | US | disclosed |
| US-6448292-B2 | COMPRISING A DIGLYCERIDE IN WHICH AT LEAST 55% BY WEIGHT OF CONSTITUTIVE ACYL GROUPS ARE UNSATURATED ACYL GROUPS AND 15 TO 100% BY WEIGHT THEREOF ARE OMEGA 3 TYPE UNSATURATED ACYL GROUPS HAVING AT LEAST 20 CARBON ATOMS AND A TRIGLYCERIDE | KAO CORPORATION (JP) | 2002-09-10 | — | — | US | disclosed |
| EP-1211305-A1 | FAT COMPOSITIONS | Kao Corporation (JP) | 2002-06-05 | — | — | EP | disclosed |
| US-20020048596-A1 | PREPARATION FOR THE TRANSPORT OF AN ACTIVE SUBSTANCE ACROSS BARRIERS | IDEA AG (DE) | 2002-04-25 | — | — | US | disclosed |
| US-20010036502-A1 | Oil composition | KAO CORPORATION (JP) | 2001-11-01 | — | — | US | disclosed |
| EP-1135991-A2 | Oil composition and use thereof | Kao Corporation (JP) | 2001-09-26 | — | — | EP | disclosed |
| US-6090565-A | Sphingoglycolipids as markers for multidrug resistant cancers | JOHN WAYNE CANCER INSTITUTE (US) | 2000-07-18 | — | — | US | disclosed |
| US-5885786-A | Methods for screening of substances for inhibition of multidrug resistance | JOHN WAYNE CANCER INSTITUTE (US) | 1999-03-23 | — | — | US | disclosed |
| WO-1997040358-A1 | MARKERS FOR MULTIDRUG RESISTANT CANCERS | JOHN WAYNE CANCER INSTITUTE (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009092-A1 | COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID | PLIN5, PHOSPHO1, PLIN3 | FAAH 94/4885TRPV1 825/4885TSHR 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.